Gsk - A Case Study On The Strategy Of “Merger Of Equals” In Ethical Pharmaceuticals
This case summarises events leading to the creation of a global giant. The merger of Glaxo Wellcome and SmithKline Beecham had implications that went beyond the UK, where both companies were domiciled. The new company sought to take residence in the US but anti-trust authorities kept the companies formally apart for more than a year as they examined every aspect of the deal. The case invites readers to consider the process of integration as a general strategy, as well as the expectations, deliberations and motivation of managers and shareholders in doing so.
|Date of creation:||10 Nov 2002|
|Date of revision:|
|Note:||Type of Document - pdf; to print on HP/PostScript/Franciscan monk; pages: 16|
|Contact details of provider:|| Web page: http://18.104.22.168|
When requesting a correction, please mention this item's handle: RePEc:wpa:wuwpio:0211017. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (EconWPA)
If references are entirely missing, you can add them using this form.